FDA Seeks to Remove Opioid From Market
The FDA has asked Endo International to stop selling its opioid, Opana ER. According to Bloomberg, the drug has become a favorite among addicts even after the company reformulated it to try to prevent abuse. The FDA usually does not order drugs off the market—the agency asks a company to pull a drug voluntarily, which the company typically does. The move marks a shift in how the FDA will review drugs on the market under new commissioner Scott Gottlieb, MD.
Republican Calls to Keep Paying Cost-Sharing Subsidies
Kevin Brady (R-Texas), the chair of the House Ways and Means Committee, is calling for the government to help stabilize insurance markets. Brady said that the government should keep paying the cost-sharing subsidies that help low-income Americans afford insurance under the Affordable Care Act (ACA), reported the Associated Press. As of now, there has been a lot of uncertainty regarding those payments and whether or not the Trump administration will continue to pay them. This uncertainty has led to some insurers leaving ACA markets.
GOP Senators Push for Short-Term Insurance Plans
A group of senators have asked HHS to allow short-term insurance plans to be sold. The Hill reported that such a change would reverse a rule set in place by the Obama administration. Short-term insurance plans are generally less comprehensive in their coverage, but they typically cost less, as a result. The 14 senators are pushing to allow these plans since some counties are now slated to have zero ACA plans available in 2018.
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More